Navigation Links
Combination treatment regimen not effective against advanced melanoma
Date:6/5/2010

CHICAGO, June 5 The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

"With each new study, we learn something important about the treatment of melanoma," said John M. Kirkwood, M.D., professor of medicine, University of Pittsburgh School of Medicine, and leader of the University of Pittsburgh Cancer Institute's (UPCI) melanoma and skin cancer program. "With this study, we learned that the addition of sorafenib, a molecular inhibitor, to a traditional chemotherapy regimen does not improve patient survival."

The phase III trial, which was sponsored by the Eastern Cooperative Oncology Group (ECOG), enrolled 823 patients from seven different sites across the country over 34 months. The primary goal of the study was to determine whether the addition of sorafenib, a molecular targeting agent, would improve survival rates for patients with metastatic melanoma when added to the chemotherapy combination of carboplatin and paclitaxel. Patients either received the chemotherapy combination alone or with sorafenib.

"While this study didn't confirm the very promising results of phase II studies with sorafenib, it is important to share its findings since the double chemotherapy combination of carboplatin and paclitaxel has achieved results that eclipse previous chemotherapy results in large phase III trials. These results take us one step closer to understanding how to most effectively treat metastatic melanoma," said Dr. Kirkwood.

Melanoma is a rare form of skin cancer, but it causes the majority of skin-cancer related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide. Surgery effectively cures early disease, but once it has spread to regional lymph nodes or distant sites, a cure is more elusive. Only two therapies in current usage have been approved by the U.S. Food and Drug Administration for treatment of advanced melanoma, and neither has been shown to prolong survival.


'/>"/>

Contact: Courtney McCrimmon
McCrimmonCP@upmc.edu
412-715-8894
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. New Drugs, New Combinations Fight Breast Cancer
2. Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling
3. Multiple myeloma patients experience high response rate with new 3-drug combination
4. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
5. Combination therapy more effective for enlarged prostate
6. Combination Treatment May Help Depressed Alcoholics
7. Researchers find new chemotherapy combination shows promise in endometrial cancer
8. Leeza Gibbons and ZERONA Equals a Winning Combination
9. Combination antibiotics effective against chlamydia-induced arthritis
10. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
11. Combination therapy targets stubborn leukemia stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a Telly Award ... four countries and millions of viewers in a partnership with the Amazon Video Direct ... and fully available on Blu Ray disc in 2018. Proceeds will be going to ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... their latest new client win in the healthcare market, with Los Angeles-based AIDS ... support healthcare staff and members. , AHF cares for nearly 800,000 individuals worldwide ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... leading manufacturers and marketers of high-quality anti-aging skincare solutions, recently announced the launch ... new products are an affordable, yet effective alternative to expensive plastic surgery or ...
(Date:8/16/2017)... , ... August 16, 2017 , ... “Mom, God's Got This: Jamie's Story” is the ... love with the Lord and has an insatiable appetite for God’s Word. , “I froze ... shelves, free gifts retrieved from packages of oatmeal. I have one to this day on ...
(Date:8/15/2017)... ... , ... The Philadelphia Marathon and the American Association for Cancer Research (AACR) ... City’s commitment to improving the health of its citizens. Dedicated to preventing and curing ... lifestyle as research shows this can help reduce the risk of cancer. ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/26/2017)... 2017 E.I. Medical Imaging (EIMI) has partnered ... custom design the worlds first ultrasound system to be used ... native habitat. In preparation for a piece produced by ... Week, Dr. Guttridge approached EIMI with the idea of an ... hammerhead sharks underwater. ...
(Date:7/25/2017)... , July 25, 2017 The med-tech biopharmaceutical ... nervous system diseases, has concluded a worldwide license agreement with ... SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement had ... Phase 2 study conducted in Europe . ... United States ...
Breaking Medicine Technology: